Home         Forums  

Go Back   Marrowforums > Bone Marrow Failure Diseases > MDS
Register FAQ Search Today's Posts Mark Forums Read

MDS Myelodysplastic syndromes

Thread Tools Search this Thread
Old Tue Apr 16, 2019, 08:37 PM
Pearl Pearl is offline
Join Date: Feb 2016
Location: New Jersey
Posts: 15

I have seen articles about CRISPR, a gene-editing technique, and I wonder if anyone is aware of advances in the use of the technique for MDS or related diseases that would be of interest to anyone at this forum.
Reply With Quote
Old Wed Apr 17, 2019, 01:18 PM
Marrowforums Marrowforums is offline
Join Date: Jul 2006
Posts: 873
The AAMDSIF Medical Advisory Board has provided an answer to your question:
CRISPR technology is a revolutionary tool that allows for efficient gene editing in a wide variety of cells. It has become invaluable in research where it can be used to make disease models in the lab. Experts have used this technique to make cancer cell lines that carry the same mutations they see in patients with MDS. They can then see how these MDS mutations change cells and how they might be targeted with specific treatments.

Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia

A new CRISPR-engineered cancer model to test therapeutics
The clinical applications of CRISPR are appropriately less further along as the safety of using this technique in patients is being studied. That said, there are several clinical trials that use CRISPR to treat diseases, including cancer, that are already open to enrollment.

In most cases the target of CRISPR is not the tumor cells as it is very difficult to make sure that every single cancer cell gets edited. Instead, the CRISPR technique has been used to modify immune cells to make them more reactive or able to recognize specific target cells like those that form tumors.

These kinds of therapies are not yet well developed for the treatment of MDS although they are in the works. There is no doubt that CRISPR techniques will become more widespread in development and delivery of anti-cancer therapies, including those designed to treat patients with MDS.
Reply With Quote
Old Thu Apr 18, 2019, 04:44 PM
Pearl Pearl is offline
Join Date: Feb 2016
Location: New Jersey
Posts: 15
I think I see in the first 2017 article that "genetic manipulation" was shown to "return" a disease process to an earlier stage.

How long does it usually take to move these prospective findings to actual clinical practice?
Reply With Quote
Old Fri Apr 19, 2019, 10:50 AM
Marlene Marlene is offline
Join Date: Oct 2006
Location: Springfield, VA
Posts: 1,333
Looks like it's still years away but it looks like many on working on different aspect of it which is a good way to move it forward quicker.

Marlene, wife to John DX w/SAA April 2002, Stable partial remission; Treated with High Dose Cytoxan, Johns Hopkins, June 2002. Final phlebotomy 11/2016. As of January 2017, FE is 233, HGB 11.7, WBC 5.1/ANC 4.0, Plts 146K.
Reply With Quote

Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

All times are GMT -4. The time now is 02:27 PM.

Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright 2006-2019 Marrowforums.org